HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Summary on May 17, 2018

May 17, 2018 - By Elizabeth Jones

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Corporate Logo

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

In total 2 analysts cover HTG Molecular Diagnostics (NASDAQ:HTGM). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 10 are the (NASDAQ:HTGM)’s analyst reports since December 27, 2017 according to StockzIntelligence Inc. On Friday, March 23 the firm has “Buy” rating given by Canaccord Genuity. On Tuesday, May 8 H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) with “Buy” rating. On Wednesday, January 24 the company was maintained by H.C. Wainwright. On Thursday, February 1 the firm earned “Buy” rating by H.C. Wainwright. On Friday, January 5 the firm has “Buy” rating by H.C. Wainwright given. On Friday, January 5 Canaccord Genuity maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) with “Buy” rating. The stock rating was maintained by H.C. Wainwright with “Buy” on Friday, March 23. On Tuesday, April 17 the rating was maintained by H.C. Wainwright with “Buy”. On Monday, January 8 the firm has “Buy” rating given by Canaccord Genuity. On Wednesday, December 27 the stock has “Buy” rating by H.C. Wainwright. Listed here are HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) PTs and latest ratings.

08/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
17/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
23/03/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $7 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
24/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
08/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
27/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

HTGM is touching $3.52 during the last trading session, after decreased 3.56%.Currently HTG Molecular Diagnostics, Inc. is downtrending after 59.58% change in last May 17, 2017. HTGM has also 207,215 shares volume. The stock underperformed the S&P 500 by 71.13%.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling.The company has $99.81 million market cap. The companyÂ’s products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies.Last it reported negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

For more HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) news brought out recently go to: Nasdaq.com, Globenewswire.com, Nasdaq.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic …” brought out on May 07, 2018, “HTG Molecular Diagnostics Reports First Quarter 2018 Results” on May 10, 2018, “HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the …” with a publish date: May 10, 2018, “New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares …” and the last “HTG Molecular Diagnostics to Announce First Quarter Financial Results and Host Conference Call on Thursday, May 10” with publication date: April 27, 2018.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.